PD-L1-stratified health-related quality of life in solid tumors: pembrolizumab versus chemotherapy-a narrative review.

Shorog E, Selvaraj L, Kandasamy G, Alzahrani TE, Almousa AF, Alenazi MA, Alshareef H, Basavan SS.

Open source

DOI: 10.3389/fmed.2026.1890061
Published: 2026-07-24
Container: Front Med (Lausanne)
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fmed.2026.1890061,
  title = {PD-L1-stratified health-related quality of life in solid tumors: pembrolizumab versus chemotherapy-a narrative review.},
  author = {Shorog E and  Selvaraj L and  Kandasamy G and  Alzahrani TE and  Almousa AF and  Alenazi MA and  Alshareef H and  Basavan SS.},
  year = {2026},
  journal = {Front Med (Lausanne)},
  doi = {10.3389/fmed.2026.1890061},
  url = {https://doi.org/10.3389/fmed.2026.1890061}
}

RIS

TY  - JOUR
TI  - PD-L1-stratified health-related quality of life in solid tumors: pembrolizumab versus chemotherapy-a narrative review.
AU  - Shorog E
AU  -  Selvaraj L
AU  -  Kandasamy G
AU  -  Alzahrani TE
AU  -  Almousa AF
AU  -  Alenazi MA
AU  -  Alshareef H
AU  -  Basavan SS.
PY  - 2026
JO  - Front Med (Lausanne)
DO  - 10.3389/fmed.2026.1890061
UR  - https://doi.org/10.3389/fmed.2026.1890061
ER  -

APA

E, S., L, S., G, K., TE, A., AF, A., MA, A., H, A., & SS., B. (2026). PD-L1-stratified health-related quality of life in solid tumors: pembrolizumab versus chemotherapy-a narrative review.. Front Med (Lausanne). https://doi.org/10.3389/fmed.2026.1890061

Source records

europe-pmc · retrieved 2026-09-26T21:03:18.470Z
doaj · retrieved 2026-09-26T21:03:18.473Z